EMA Authorised: Xenpozyme (olipudase alfa) — Sanofi B.V.

View source ↗

Summary

The EMA authorised Xenpozyme (olipudase alfa) for the treatment of Acid sphingomyelinase deficiency (ASMD) types A/B or type B. It has been designated as an orp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acid Sphingomyelinase Deficiency

Drugs mentioned

• XENPOZYME (olipudase alfa-RPCP)

Snippet

Status: Authorised. Therapeutic area: Acid sphingomyelinase deficiency (ASMD) type A/B or type B. MAH: Sanofi B.V.. Decision date: 08/01/2026. Orphan medicine